📰 Exact Sciences News
Page 10 - Exact Sciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Exact Sciences. Real-time updates on events, politics, business and more.
February 29, 2024
The test, using blood or saliva, can evaluate genetic risk for colorectal, breast, prostate, skin, ovarian, endometrial, pancreatic, gastric, kidney and endocrine cancers.
February 29, 2024
The test, using blood or saliva, can evaluate genetic risk for colorectal, breast, prostate, skin, ovarian, endometrial, pancreatic, gastric, kidney and endocrine cancers.
February 29, 2024
The test, using blood or saliva, can evaluate genetic risk for colorectal, breast, prostate, skin, ovarian, endometrial, pancreatic, gastric, kidney and endocrine cancers.
February 28, 2024
MADISON, Wis.--(BUSINESS WIRE)--Feb 28, 2024--
February 28, 2024
28.02.2024 - Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the launch of the Riskguard hereditary cancer test in the United States. The Riskguard test provides an individualized patient report that includes ... Seite 1
February 28, 2024
Exact Sciences Co. (NASDAQ:EXAS – Free Report) – Investment analysts at Leerink Partnrs boosted their Q1 2024 EPS estimates for Exact Sciences in a research note issued to investors on Wednesday, February 21st. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will earn ($0.36) per share for the quarter, up from […]
February 28, 2024
The test, using blood or saliva, can evaluate genetic risk for colorectal, breast, prostate, skin, ovarian, endometrial, pancreatic, gastric, kidney and endocrine cancers.
February 28, 2024
The test, using blood or saliva, can evaluate genetic risk for colorectal, breast, prostate, skin, ovarian, endometrial, pancreatic, gastric, kidney and endocrine cancers.
February 28, 2024
The test, using blood or saliva, can evaluate genetic risk for colorectal, breast, prostate, skin, ovarian, endometrial, pancreatic, gastric, kidney and endocrine cancers.